Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma
2021 · Nature Communications · 46 citations
https://doi.org/10.1038/s41467-021-25469-8
P
Patrick Blaney
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
384
Papers
559
Citations
12
h-index
14
i10-index
Patrick Blaney is an academic researcher from NYU Langone Health. The author has contributed to research in topics: Multiple Myeloma Research and Treatments & Protein Degradation and Inhibitors & Peptidase Inhibition and Analysis. The author has an h-index of 12, co-authored 327 publications.
ORCID: 0000-0002-9319-8866Papers by this author
worksInsights into high-risk multiple myeloma from an analysis of the role of PHF19 in cancer
2021 · Journal of Experimental & Clinical Cancer Research · 11 citations
https://doi.org/10.1186/s13046-021-02185-1
1q amplification and PHF19 expressing high-risk cells are associated with relapsed/refractory multiple myeloma
2024 · Nature Communications · 11 citations
https://doi.org/10.1038/s41467-024-48327-9
Data from Impact of Rare Structural Variant Events in Newly Diagnosed Multiple Myeloma
2024 · 0 citations
https://doi.org/10.1158/1078-0432.c.7054118.v1
P-231 Whole Genome Sequencing Reveals Lower APOBEC-Mutational Activity in Multiple Myeloma Patients With African Ancestry Compared With Those of Non-African Ancestry
2024 · Clinical Lymphoma Myeloma & Leukemia · 0 citations
https://doi.org/10.1016/s2152-2650(24)02134-7
Supplementary Table S1 from Multiomic mapping of acquired chromosome 1 copy number and structural variants to identify therapeutic vulnerabilities in multiple myeloma.
2024 · 0 citations
https://doi.org/10.1158/1078-0432.27033235
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat